Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
about
Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cellsGenetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Modeling Philadelphia chromosome positive leukemias.Farnesyltransferase inhibitors: mechanism and applications.Prospects for anti-ras drugs.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.Philadelphia-positive leukemia: a personal perspective.BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Non Digestible Oligosaccharides Modulate the Gut Microbiota to Control the Development of Leukemia and Associated Cachexia in Mice.Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.Recent advances in targeted therapy of human myelogenous leukaemia.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Lonafarnib in cancer therapy.Emerging drugs in chronic myelogenous leukaemia.Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasClinical activity of tipifarnib in hematologic malignancies.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Ras as a therapeutic target in hematologic malignancies.Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokinesMolecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Lonafarnib for cancer and progeria.Grb10 is involved in BCR-ABL-positive leukemia in mice.Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells.
P2860
Q31055456-896E37C0-A587-40CA-9D40-BED6F2E6A2B0Q33270804-629ECF2F-118B-43DE-B1C9-9E3067B8C4C1Q33847866-FCBA3852-99A1-49C2-B72A-5019DF85F4F3Q33914284-D7302070-2C06-46C7-8E22-E0B2F27F9A95Q34405446-53833CAD-45CE-453F-9BA5-41BF32E7A401Q34481874-D9F25BA4-3D7A-41CF-964F-E9D7FC02CCB0Q34534438-50F36758-B0E3-4045-B8D4-29E41E1A4BA0Q34651253-E8735B88-763D-4669-A3E2-A49FE73A6310Q34929081-41814C24-89A8-4E12-88EE-A2D0DAF858B9Q35022502-46D804D5-6F0E-4196-87DF-313498A33D2FQ35022511-221C5F95-9E4B-436F-8F28-C0B75EB65434Q35128883-7BA43CC7-A313-4B19-B972-B448EB56B0D1Q35166848-B64400BB-45B5-49F4-BB01-735DA7514754Q35186888-D9587380-2079-4D2E-B20A-2A3FB8ABC5FFQ35670313-4B3BFD3B-7F1E-4715-BCE5-3829D018B1DDQ35735401-44C19ED9-186C-4B26-8D98-E6AE1183F955Q35773205-48022E53-5D4A-4656-A159-E24EBE0D782BQ35816396-29571D53-A641-44E3-9568-2103A7C4B379Q35932017-740A0396-0CA1-4410-8E18-A85E78FD512FQ36318531-C051C100-4AF7-432A-8FD0-8E30D57EC213Q36334327-82AC978E-F574-4144-B10A-4018DE5F84E3Q36429603-1672A586-369B-4E47-83BD-20F7742DBA5EQ36491847-F6AB70C2-4402-43AE-85CE-D0D592ECDC5DQ36634266-E7680399-FFC4-4619-9E64-5BC876A21604Q36693797-77065C7B-1377-49A9-8BBF-4017270D8F6EQ36736368-B3E8E87D-8076-498A-81B3-011BA5AF2E5AQ36822880-6EAB8221-2404-429C-8DE6-50E12DF418E2Q36866611-6D551BAC-B8B8-4A86-806A-6A5A3A381A49Q36946766-9BD52AC7-396D-461E-892D-2311D7443ABDQ37162871-5F193E77-B538-4F75-A523-DBB89123FE1AQ37183513-C1DDDE75-91C2-40B6-B57C-CFE5FA24569FQ37847179-F11EEA9F-B1D7-4B86-8EF4-44D05DBDA764Q38012480-04015A19-1E7B-4FB4-92DF-81B9B5BBCE30Q38953915-475A4DAF-3CF0-47DE-AF57-D2CA4EAAFFC2Q39705925-F3774268-5712-437D-8E17-477E81BEDAE5Q40146009-6D800000-CCB8-439B-BA24-C5E966B93946Q40152780-E4979AC3-5DB2-41F8-A7C4-2A7AF6C7281FQ40423639-EE8DCC98-3A64-4310-8C4F-FE4951805F0FQ40478997-F7B2028E-F2B8-47C3-B75F-D253EF2DD16BQ40720447-A01521EF-6B64-4A1A-B9AB-42CC06AAA507
P2860
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@ast
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@en
type
label
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@ast
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@en
prefLabel
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@ast
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@en
P2093
P356
P1433
P1476
Activity of the farnesyl prote ...... with chronic myeloid leukemia.
@en
P2093
D G Peters
M J Gerlach
P Kirschmeier
R R Hoover
W R Bishop
P304
P356
10.1182/BLOOD.V97.5.1404
P407
P577
2001-03-01T00:00:00Z